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BRCA1 is a breast and ovarian tumor suppressor. Hereditary mutations in BRCA1
result in a predisposition to breast cancer, and BRCA1 expression is down-regulated
in ∼30% of sporadic cases. The function of BRCA1 remains poorly understood, but
it appears to play an important role in DNA repair and the maintenance of genetic
stability. Mouse models of BRCA1 deficiency have been developed in an attempt to
understand the role of the gene in vivo. However, the subtle nature of BRCA1 function
and the well-known discrepancies between human and murine breast cancer biology
and genetics may limit the utility of mouse systems in defining the function of BRCA1 in
cancer and validating the development of novel therapeutics for breast cancer. In contrast
to mice, pig biological systems, and cancer genetics appear to more closely resemble
their human counterparts. To determine if BRCA1 inactivation in pig cells promotes their
transformation and may serve as a model for the human disease, we developed an
immortalized porcine breast cell line and stably inactivated BRCA1 using miRNA. The cell
line developed characteristics of breast cancer stem cells and exhibited a transformed
phenotype. These results validate the concept of using pigs as a model to study BRCA1
defects in breast cancer and establish the first porcine breast tumor cell line.
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Introduction
Breast cancer is a leading cause of death in women and is one of the most common cancers in the
world today. Up to 40,000 women are expected to die of breast cancer annually in the US alone
(Siegel et al., 2011). The underlying causes of breast cancer development remain very much under
investigation, but we now know that the BRCA1 tumor suppressor gene plays an important role in
many breast cancers. Women who carry a BRCA1 germ line mutation have a cumulative lifetime
risk of 50–85% of developing breast cancer (King et al., 2003). Although somatic BRCA1mutations
are rare in sporadic breast cancer, BRCA1 expression is down-regulated in∼30% of sporadic cases
by allele loss or epigenetic mechanisms (Welcsh and King, 2001; Yang et al., 2001).
The function of BRCA1 remains poorly understood. It has a ubiquitin ligase activity and can
control the stability/activity of proteins such as Claspin (Sato et al., 2012) and estrogen receptor
alpha (Savage and Harkin, 2015). It is also a key player in modulating DNA repair (Zhang and
Powell), replication fork stability (Pathania et al., 2011), senescence (Tu et al., 2013), oxidative
stress (Marks, 2013), genomic stability (Savage and Harkin, 2015), and checkpoint induced cell
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cycle arrest (Huen et al., 2010). The complex role of BRCA1 in
cellular homeostasis has made elucidating its key functions in
cancer difficult.
Mouse models of BRCA1 deficiency have been developed
in an attempt to understand the role of the gene in vivo (Ma
et al., 2010). Although BRCA1 knockout provokes embryonic
lethality in mice, conditional knockout of BRCA1 in breast tissue
leads to tumor development after a long latency. The latency
period can be strongly reduced by introducing defects in the p53
tumor suppressor to the animal system. These animal models
have allowed the validation of therapies designed against BRCA1
defective tumors. However, even therapeutic approaches that
were effective resulted in the emergence of resistant tumors (Ma
et al., 2010). Further studies to examine approaches to overcome
the resistance are limited by the short lifespan of the mice.
Moreover, the subtle nature of BRCA1 function and the well-
known discrepancies between human and murine breast biology
(Dine and Deng, 2013) and cancer genetics (Kendall et al., 2005)
may limit the utility of mouse systems in defining the function of
BRCA1 in human cancer.
In contrast to mice, pigs exhibit very similar cancer genetics
to humans (Adam et al., 2007). Moreover, their physiology and
biochemistry is similar (Swindle et al., 2012) and their lifespan
extends for decades. Consequently, a porcine model for breast
cancer could prove a powerful tool for validating breast cancer
therapies, preventative strategies and the clinical response to the
emergence of drug resistance.
In order to validate the use of porcine systems in breast cancer
research, we generated an immortalized porcine breast cell line
using the SV40 LT oncoprotein (Chen and Hahn, 2003). We
then used BRCA1 miRNA to generate a stable matched pair of
cell lines that are positive or negative for BRCA1 expression.
Characterization of the cells showed that BRCA1 knockdown
induced enhanced growth and induced a transformed phenotype
on the cells. Moreover, the transformed cells expressed markers
characteristic of cancer stem cells. These results establish the first
porcine breast cancer cell line and validate the concept of using
porcine systems as a model to study BRCA1 defects in breast
cancer.
Materials and Methods
Porcine Cell Lines and Transfections
Primary porcine breast epithelia cells were isolated as described
in Prather et al. (1999) using a protocol approved by the IACUC
of the University of Missouri-Columbia, Columbia, Missouri.
They were transfected with pbabe puro SV40LT (Addgene
#13970) using Lipofectamine 2000 (Invitrogen, Carlsbad CA)
according to the manufacturer’s instructions. Cells were selected
in puromycin (Sigma, St Louis, MO) at 1µg/ml. miRNA
sequences corresponding to two different regions of porcine
BRCA1 were designed using the Block-iT™ RNAi Designer
(Invitrogen). Two single-stranded DNA oligonucleotides were
designed for each sequence, one encoding the target pre-miRNA
(top strand) and the other, its compliment (bottom). Each
oligonucleotide also contained five nucleotides (TGCTG)
derived from the endogenous miR-155 at the 5′ end and 19
nucleotides derived from miR-155 to form a terminal loop. The
sequences of the two different oligo sets are as follows: #1 Top:
5′-TGCTGATTGTTTGCAAACTGCAATCCGTTTTGGCCAC
TGACTGACGGATTGCATTGCAAACAAT-3′, #1 Bottom: 5′-C
CTGATTGTTTGCAATGCAATCCGTCAGTCAGTGGCCAA
AACGGATTGCAGTTTGCAAACAATC-3′; #2 Top: TGCTG
TATTAAAGCACCATGAGGGTCGTTTTGGCCACTGACTG
ACGACCCTCAGTGCTTTAATA-3′; #2 Bottom: 5′-CCTGTAT
TAAAGCACTGAGGGTCGTCAGTCAGTGGCCAAAACGA
CCCTCATGGTGCTTTAATAC-3′.
The corresponding single-stranded oligos were annealed to
generate a double-stranded oligo which was then cloned into the
pcDNA™ 6.2-GW/EmGFP-miR vector (Invitrogen). Generation
of the double-stranded oligos and cloning into the expression
vector were performed using the BLOCK-iT™ Pol II miR
RNAi Expression Vector Kit (Invitrogen) as described by the
manufacturer. Stable transfectants were generated by transfecting
the transformed pig mammary epithelial cells with 2µg of the
two different miRNA expression vectors, as well as a negative
control consisting of amiRNA to LacZ, using Lipofectamine 2000
according to the manufacturer’s instructions and selecting with
Blasticidin (4µg/ml).
qRT-PCR
qRT-PCR was performed on total RNA isolated from the cells
with Trizol using an iCycler Real-Time Detection System (Bio-
Rad Laboratories, Inc., Hercules, CA) with the Quantitect SYBR
Green RT-PCR Kit (Qiagen, Inc., Valencia, CA) as per the
manufacturer’s instructions. The fold change for each gene was
calculated using the 2−11CT method (Livak and Schmittgen,
2001) with GAPDH as the reference gene. The primers
used were BRCA1 For: 5′-GTCCAAAGCGAGCAAGAGAA -3′,
BRCA1 Rev: 5′- ACAGAAGCCCCACAGAGGA -3′; GAPDH
For: 5′- CGATGCTGGTGCTGAGTATG- 3′, GAPDH Rev: 5′-
GAAGGGGCAGAGATGATGAC- 3′.
Western Blots
Total cell lysates were prepared by lysing the cells in
modified RIPA buffer (150mM NaCl, 50mM Tris, pH 7.5,
1% NP-40) supplemented with 100µg/ml leupeptin, 100µg/ml
aprotinin and 1mM sodium orthovanadate. BRCA1 and ALDH1
antibodies were obtained from Santa Cruz Biotechnology, Santa
Cruz, CA., Actin antibodies were from Sigma (St. Louis MO)
and EpCAM antibodies were from AbCam. HRP conjugated
Trueblot secondary antibodies were purchased from eBioscience
(eBioscience Inc. San Diego, CA) and western blots were
developed using a Pierce ECL detection system (Thermo
Scientific, Rockford IL).
Growth Curves
2× 104 cells/well were plated in six-well plates in normal growth
medium and incubated for 6 days. Cell number was determined
each day by counting the number of viable cells. Experiments
were performed twice in duplicate.
Matrigel
Fifty micro liters of Matrigel (BD Biosciences, San Jose, CA) was
plated in a 96 well plate and allowed to set. Cells were trypsinized,
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washed in growth medium and plated at 5000 cells per well in
100µl of growth medium. Hundred micro liters of medium+4%
Matrigel was added and the medium changed every 4 days.
Soft Agar
Six well plates were prepared with 2ml bottom agar (16ml 1.8%
molten Difco Bacto agar cooled to 42◦C and mixed with 1.6ml
serum, 1.6ml 10X PBS and mixed with 30.3ml DMEM) and
allowed to set. Cells were trypsinized, washed, and 3 × 104 cells
suspended in 1.5ml growth medium. Three milli liters of liquid
bottom agar was added to the cell dilution and 1.5ml aliquoted
into each well to set.
Anoikis
Twelve well plates were treated with polyHEMA (Sigma) and
allowed to dry overnight. 1 × 106 cells were plated in each well
and the cell viability measured after 48 h by trypan blue exclusion.
Results
Generation of an Immortalized Porcine Epithelial
Cell Line
Primary pig breast epithelial cells were isolated as described
previously (Prather et al., 1999) and transfected with an SV40
LT expression vector. Transfected cells were isolated by selection
in puromycin and surviving colonies pooled. As the cells were
passaged, the SV40 LT transfected cells lost the senescent
morphology apparent in the parental cells (Figure 1). They
were then serially passaged to determine if they had been
immortalized. Transfected cells have been passaged more than
26 times without apparent loss of viability. In contrast, parental
cultures lose proliferative capacity by passage 8.
Identification of an Effective Porcine BRCA1
miRNA
The Block-iT™ RNAi Designer tool from Invitrogen was
used to identify potentially effective miRNA sequences against
porcine BRCA1. Two were generated and cloned into the
vector pcDNA GW 6.2 EmGFPmiRNA. The vectors were then
transiently transfected into the immortalized breast epithelial
cells and assayed for the degree of knockdown by RT-PCR.
Only one of the miRNAs proved effective (Figure 2A). This
FIGURE 1 | Immortalization of pig mammary epithelial cells. Primary pig
breast epithelial cells were stably transfected with an SV40 LT expression
construct and selected in puromycin. Surviving cells were serially passaged to
confirm immortalization.
miRNA and the empty vector were stably transfected into the
immortalized pig breast cells to generate a matched pair+/− for
BRCA1. Western analysis confirmed that the miRNA transfected
cells had almost completely lost BRCA1 protein expression
(Figure 2B).
Suppression of BRCA1 Enhances Porcine
Epithelial Cell Growth
As the cells were passaged, the BRCA1 suppressed cells
progressively adopted a noticeably different morphology than the
vector control cell line (Figure 3A). To characterize the effect
of the BRCA1 suppression on the cell cycle, we measured the
relative growth of the matched pair of cell lines transfected with
vector or miBRCA1. Cells were plated and counted every day
for 1 week. The BRCA1 suppressed cells exhibited an enhanced
growth rate (Figure 3B).
Suppression of BRCA1 Alters Differentiation
Non-transformed human breast epithelial cell lines can be
induced to differentiate into acini with hollow lumens when
plated in 3D in matrigel. This differentiation is thought to mimic
the process that occurs during the development of breast ducts.
The process is disrupted by suppression of BRCA1 (Furuta
et al., 2005). To examine the loss of BRCA1 in porcine cells
on this process, we plated the BRCA1+/− matched cell lines
in matrigel for 10 days. After 10 days, the immortalized cells
transfected with vector alone formed acini, reminiscent of human
immortalized breast cells. The BRCA1 knockdown cells mostly
grew as disordered masses (Figure 4).
Suppression of BRCA1 Promotes Transformation
The BRCA1 knockdown appeared to have induced enhanced
growth and reduced differentiation (Figures 3, 4). In order
FIGURE 2 | miRNA-mediated BRCA1 knockdown in the immortalized
pig mammary epithelial cells. (A) The immortalized pig breast epithelial cells
were transiently transfected with expression constructs for two BRCA1
miRNAs and a LacZ control. Forty-eight hours later, BRCA1 mRNA levels were
determined by qRT-PCR analysis. (B) The immortalized pig mammary
epithelial cells were transfected with BRCA1 miRNA#1 or the miLacZ control
and selected with blasticidin to obtain cells that were stably knocked down for
BRCA1. Western blot analysis confirmed efficient knockdown. β-actin served
as control for equal protein loading. Error bars show standard error, p < 0.05
for miRNA#1, mRNA #2 was not significant.
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FIGURE 3 | Loss of BRCA1 enhances pig mammary
epithelial cell growth. (A) Serially passaging the pig
mammary epithelial cells stably knocked down for BRCA1
resulted in an altered morphology compared to those cells
stably expressing the LacZ miRNA. (B) 2× 104 cells/well were
plated in 6-well plates and cell growth was determined by
counting the number of cells at the indicated times. Error
bars show standard error, p < 0.05.
FIGURE 4 | Loss of BRCA1 inhibits acini formation. The −/+ BRCA1 pig
mammary epithelial cells were plated in matrigel and allowed to grow for 10
days. Control cells formed acinus-like structures after 3D growth whereas the
cells stably expressing BRCA1 miRNA grew as disordered masses. Error bars
show standard error, p < 0.05.
to determine if it was sufficient to induce the tumorigenic
phenotype, we plated the cells in soft agar and counted colony
formation after 14 days. Anchorage-independent growth is one
of the hallmarks of cell transformation and is considered the
most accurate and stringent in vitro assay for detecting malignant
transformation of cells (Colburn et al., 1978). Figure 5A
shows that the BRCA1 positive cells failed to form colonies
in agar. In contrast, the BRCA1 knockdown cells formed
numerous, large colonies, indicative of highly transformed
cells.
Suspension of normal cells results in the induction of
apoptosis, a process called anoikis. Transformed cells typically
resist anoikis, and this may contribute to their ability to
proliferate when suspended in soft agar (Guadamillas et al.,
2011). Examination of the ability of the cells to survive
suspension showed that the BRCA1 knockdown cells were
resistant (Figure 5B).
FIGURE 5 | Loss of BRCA1 enhances the transformed phenotype of pig
mammary epithelial cells. (A) The pig breast epithelial cells stably
expressing BRCA1 miRNA were plated in soft agar and scored for growth 14
days later. Representative photomicrographs are shown in the top panel and
data from three independent experiments quantitated in the bar graph in the
lower panel. (B) 1× 106 cells/well were plated in polyHEMA-coated 12-well
plates and cell viability assessed 48 h later by trypan blue staining. Error bars
show standard error, p < 0.05.
BRCA1 Knockdown Promotes a CSC Phenotype
In primary breast cells, knockdown of BRCA1 blocks the
differentiation of stem/progenitor cells and enhances their
proliferation (Furuta et al., 2005; Ma et al., 2010). Moreover, the
ability to grow in soft agar is typically associated with the cancer
stem cell (CSC) population of a transformed culture (Colburn
et al., 1978). To determine if the knockdown of BRCA1 had
promoted the development of CSC phenotype, we performed
Western analysis for the expression of the CSC markers EpCAM
(Dawood et al., 2014) as well as ALDH1 (Moreb, 2008). We
found that in the BRCA1 knockdown cells, the EpCAM CSC
marker was massively upregulated, and ALDH1 was upregulated
three-fold (Figure 6). Actin served as a loading control. In these
experiments, we had included miRNA against a second tumor
suppressor, RASSF1A (Donninger et al., 2007), as an additional
negative control. Whereas, the RASSF1AmiRNA had no obvious
effect on EpCAM, it did upregulate ALDH1, although less than
the miBRCA1. Thus, RASSF1A may also be involved, to some
extent, in CSC regulation.
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FIGURE 6 | BRCA1 knockdown in pig mammary epithelial cells alters
CSC marker expression. Equal amounts of protein lysates from control and
BRCA1 knockdown cells were fractionated on SDS polyacrylamide gels and
western blotted with an anti-EpCAM antibody and an ALDH1 antibody. β-actin
was used a protein loading control. Mi_lacZ and a non BRCA1 miRNA
transfected cell line (mi_RASSF1A) served as negative control cell lines.
Discussion
Women who carry a BRCA1 germ line mutation have a
cumulative lifetime risk of 50–85% of developing breast cancer
(King et al., 2003). Although somatic BRCA1 mutations are rare
in sporadic breast cancer, BRCA1 expression is down regulated
in ∼30% of sporadic cases (Yang et al., 2001). Its mode of action
appears complex, subtle and remains only partially understood.
It has been shown to modulate DNA repair, DNA damage
checkpoints, stability of Claspin and Estrogen receptor alpha, and
to modulate cell adhesion and motility (Wang, 2012; Christou
and Kyriacou, 2013). Its loss of function in human cells is thought
to promote genetic instability, hence leading to the development
of cancer. It has been shown to synergize with the p53 tumor
suppressor in mouse models and human cell tissue culture
experiments (Brodie and Deng, 2001; Hartman and Ford, 2003).
Although mouse model systems have proven to be powerful
tools in the investigation of the nature of cancer in vivo, they
suffer from a major drawback. Murine cancer genetics is much
simpler than that of humans. Murine cells are much easier
to transform than human cell systems. Whereas, human cells
require at least five genetic lesions to convert from a normal cell
to a tumor cell, mouse cells can be induced to transform by just
two oncogenic lesions (Rangarajan et al., 2004; Kendall et al.,
2005). Thus, mouse models may prove inaccurate when trying to
model human cancer. In contrast, porcine cancer genetics is very
similar to human cells. Pig cells require five or more oncogenic
mutations to undergo transformation, much like humans (Adam
et al., 2007). Thus, a pig cancer model is more likely to accurately
reflect the human condition.
Nothing is known about the role of BRCA1 in porcine cells
and whether its ablation phenocopies the human state. Here,
we have attempted to address the issue by generating the first
immortalized porcine breast cell line by introducing an SV40 LT
expression plasmid into primary breast cells derived from a pig.
SV40 LT can immortalize human cells impairing the function of
both the p53 and the Rb tumor suppressors (Ahuja et al., 2005).
In experimental human cell systems, SV40 LT transduction has
been shown to promote a transcriptional fingerprint which is
quite reminiscent of that observed in triple negative breast cancer
primary tumors (Deeb et al., 2007), suggesting the lesion is a
relevant model. We found that it is also effective in a porcine
system. We then examined the effects of inactivating BRCA1 in
the immortalized cells.
To knockdown BRCA1, we used a stable miRNA expression
approach. Although we assayed two different miRNA sequences,
only one was really effective as measured by qRT-PCR,
and so this is the sequence we used in the experiments.
Subsequent examination of BRCA1 protein levels by Western
blot showed that thismiRNA rendered the BRCA1 protein almost
undetectable. The knockdown of BRCA1 in a background where
SV40LT has impaired p53 and Rb function was sufficient to
promote enhanced growth and a dramatic transformation of
the cells, as measured by colony formation in soft agar. Thus,
we have created the first porcine breast epithelial tumor cell
line.
BRCA1 down-regulation has been implicated in the
development of a cancer stem cell-like phenotype in breast
cells (Liu et al., 2008). In vitro, it appears that it is the CSC
population that provides the ability to form colonies in soft agar
(Colburn et al., 1978). When we examined the cells we found that
the inactivation of BRCA1 in the SV40 LT background induced
the upregulation of the CSC markers EpCAM (Munz et al., 2009)
and ALDH1 (Moreb, 2008). This suggests that breast cancer
CSC in humans and pigs are regulated in a similar manner by
BRCA1.
This work establishes the first porcine model system for
studying BRCA1 and breast cancer. It validates the concept
that porcine transgenic animal models may be valuable for the
study of human breast cancer and the development of novel
therapeutics for the treatment of breast cancer driven by BRCA1
defects. In particular, due to the human-like life span of pigs, a
porcine model of BRCA1 driven breast cancer could allow the
testing of long term preventative measures, as well as strategies
to counter the persistence of minimal residual disease after
treatment. Attempts have been previously made to develop such
an animal (Luo et al., 2011). Unfortunately, no animal’s survived
BRCA1 knockout long enough to determine any biological effects
on breast cancer. These experiments suggest that a future porcine
BRCA1 system would need to involve a tissue specific knockout,
as has been the case in transgenic mouse systems.
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